These days Bristol-Myers Squibb Co.'s immunology expertise is most often associated with its immuno-oncology blockbusters, but the company is also focused on expanding its position in autoimmune diseases, which is anchored by Orencia (abatacept).
In fact, Orencia – a selective T-cell co-stimulation modulator targeting CD80 and CD86 – won its initial US FDA approval...






![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
